Haptoglobin Phenotype and Levels in Type 2 Diabetes and Effects of Fenofibrate

被引：0
|
作者：
Januszewski, Andrzej S.
Young, Hayden K.
Li, Liping
Oconnell, Rachel L.
Lyons, Timothy
Kelly, Clare B.
Sullivan, David
Scott, Russell
Keech, Anthony C.
Jenkins, Alicia
机构：
来源：
DIABETES | 2019年 / 68卷
基金：
英国医学研究理事会;
关键词：
D O I：
10.2337/db19-139-LB
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
139-LB
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Predictors of peripheral neuropathy and effects of fenofibrate among 9,795 subjects with type 2 diabetes: the fenofibrate intervention and event lowering in diabetes (FIELD) study
    Keech, A. C.
    Rajamani, J. K.
    Best, J. D.
    Hankey, G.
    Donoghoe, M. W.
    Li, L.
    Jenkins, A. J.
    Ting, R.
    Davis, T. M. E.
    Phillips, P.
    Barter, P.
    DIABETOLOGIA, 2011, 54 : S81 - S82
  • [42] Effects of fenofibrate on silent myocardial infarction, hospitalization for acute coronary syndromes and amputation in type 2 diabetes: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    Burgess, David
    Hunt, David
    Li, LiPing
    Zhang, Jun
    Sy, Ray
    Laakso, Markku
    Davis, Tim
    Colman, Peter
    Forder, Peta
    Williamson, Elizabeth
    Pike, Rhana
    Keech, Anthony
    CIRCULATION, 2007, 116 (16) : 838 - 838
  • [43] Haptoglobin phenotype and vascular complications in patients with diabetes.
    Levy, AP
    Roguin, A
    Hochberg, I
    Herer, P
    Marsh, S
    Nakhoul, FM
    Skorecki, K
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (13): : 969 - 970
  • [44] Erratum to: Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    Michael C. d’Emden
    Alicia J. Jenkins
    Liping Li
    Diana Zannino
    Kristy P. Mann
    James D. Best
    Bronwyn G. A. Stuckey
    Kris Park
    Juha Saltevo
    Anthony C. Keech
    Diabetologia, 2015, 58 : 2200 - 2200
  • [45] Haptoglobin Phenotype Modulates Lipoprotein-Associated Risk for Preeclampsia in Women With Type 1 Diabetes
    Kelly, Clare B.
    Yu, Jeremy Y.
    Jenkins, Alicia J.
    Nankervis, Alison J.
    Hanssen, Kristian F.
    Garg, Satish K.
    Scardo, James A.
    Basu, Arpita
    Hammad, Samar M.
    Aston, Christopher E.
    Lyons, Timothy J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (10): : 4743 - 4755
  • [46] Effects of fenofibrate therapy on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus
    Asano, A
    Kobayashi, J
    Murase, Y
    Nohara, A
    Kawashiri, MA
    Inazu, A
    Shimizu, M
    Mabuchi, H
    PHARMACOTHERAPY, 2006, 26 (04): : 447 - 451
  • [47] Haptoglobin Phenotype Modulates Lipoprotein-Associated Risk for Preeclampsia in Women with Type 1 Diabetes
    Kelly, Clare B.
    Yu, Jeremy
    Jenkins, Alicia
    Nankervis, Alison J.
    Hanssen, Kristian F.
    Garg, Satish K.
    Aston, Christopher E.
    Lyons, Timothy
    DIABETES, 2018, 67
  • [48] Low-molecular weight fluorophores in type 2 diabetes: associations with diabetes complications and effects of fenofibrate in the FIELD study
    Chen, D.
    Januszewski, A. S.
    Scott, R. S.
    O'Connell, R. L.
    Aryal, N. R.
    Sullivan, D. R.
    Watts, G. F.
    Taskinen, M. -R.
    Barter, P. J.
    Best, J. D.
    Simes, J.
    Keech, A. C.
    Jenkins, A. J.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S457 - S457
  • [49] Effects of long-term fenofibrate therapy on cardiovascular events in people with type 2 diabetes mellitus
    Charles A. Reasner
    Current Atherosclerosis Reports, 2006, 8 (4) : 261 - 262
  • [50] Haptoglobin Phenotype and Intensive Glycemic Control for Coronary Artery Disease Risk Reduction in People With Type 2 Diabetes: The ADVANCE Study
    Cahill, Leah E.
    Warren, Rachel A.
    Carew, Allie S.
    Levy, Andrew P.
    Sapp, John
    Samuel, Michelle
    Selvin, Elizabeth
    Lavallee, Samantha K.
    Poulter, Neil
    Marre, Michel
    Harrap, Stephen
    Mancia, Giuseppe
    Harris, Katie
    Chalmers, John
    Woodward, Mark
    Rimm, Eric B.
    DIABETES CARE, 2024, 47 (05) : 835 - 843
12345